3D Signatures (TSX-V:DXD) has appointed Joost van der Mark as its chief business officer, effective Jan. 6.
Mr. van der Mark brings more than two decades of executive experience to 3DS, having worked with several major international healthcare companies as well as earlier stage biotechnology and healthcare firms.
He joins 3DS from BioSyent, where he served as VP of corporate development, with responsibility for business development and market access initiatives. Prior to BioSyent, Mr. van der Mark co-founded Orphan Canada, which subsequently sold its assets to Knight Therapeutics in 2014. In a career spanning more than two decades, he has also held progressive positions at Bayer, Sanofi and Nycomed.
In a statement, 3Ds CEO, Jason Flowerday, said Mr. van der Mark is a seasoned leader with a strong track record of delivering strategic guidance and profitable growth to both major international pharmaceutical companies and emerging healthcare companies.
“I have tremendous confidence in his ability to help us establish valuable pharma and lab partnerships, determine our business development priorities and sharpen our overall execution,” Mr. Flowerday added.